Cargando…
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
OBJECTIVE: Create a timeline of diagnosis and treatment for IPF in the US. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis was performed in collaboration with the OptumLabs Data Warehouse using an administrative claims database of Medicare Fee for Service beneficiaries. Adults 50 and ove...
Autores principales: | Herberts, Michelle B., Teague, Taylor T., Thao, Viengneesee, Sangaralingham, Lindsey R., Henk, Henry J., Hovde, Kevin T., Dempsey, Timothy M., Limper, Andrew H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398946/ https://www.ncbi.nlm.nih.gov/pubmed/37532984 http://dx.doi.org/10.1186/s12890-023-02565-7 |
Ejemplares similares
-
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021) -
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022) -
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis
por: Teague, Taylor T., et al.
Publicado: (2022) -
The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research
por: Dempsey, Timothy M., et al.
Publicado: (2023) -
Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
por: Dempsey, Timothy M., et al.
Publicado: (2021)